L. Savegnago et al. / Tetrahedron Letters 54 (2013) 40–44
43
Table 4
Antioxidant activity of compound 3a on FRAP and linoleic acid oxidation assays
(l
M)
% Oxidation linoleic acid
(lM)
FRAP (abs)
50
100
500
1000
Imax (%)
77.71 1.48⁄⁄⁄
50.38 4.97⁄⁄⁄
38.39 3.48⁄⁄⁄
32.48 4.37⁄⁄⁄
67.52
10
50
75
100
0.089 0.009⁄
0.167 0.027⁄⁄
0.239 0.029
0.305 0.027⁄⁄
Each value is expressed as mean S.E.M (n = 4). (⁄) Denote p <0.05; (⁄⁄) p <0.01; (⁄⁄⁄) p <0.001 as compared to the respective control
sample (one way ANOVA/Newman-Keuls). Imax: maximal inhibition (%). Abs = absorbance.
Table 5
Antioxidant activity of compound 3a on TBARs induced by SNP in mice
TBARS (% oxidation)
Cortex
(l
M)
Hippocampus
(lM)
(l
M)
Cerebellum
50
75
100
—
Imax (%)
34.97 19.16⁄⁄
31.99 15.12
27.79 13.07⁄⁄
—
5
10
50
100
Imax (%)
74.27 1.57⁄⁄
68.15 3.69⁄⁄⁄
17.56 3.00⁄⁄⁄
17.76 5.75⁄⁄⁄
82.44
10
25
50
100
Imax (%)
40.32 6.9⁄⁄⁄
29.48 9.49⁄⁄⁄
17.67 1.46⁄⁄⁄
26.30 12.75⁄⁄⁄
82.33
72.21
Each value is expressed as mean S.E.M (n = 4). (⁄) Denote p <0.05; (⁄⁄) p <0.01; (⁄⁄⁄) p <0.001 as compared to the induced (SNP-100% of oxidation) (one way ANOVA/Newman-
Keuls). Imax: maximal inhibition (%).
T. Organoselenium Chemistry: Synthesis and Reactions; Wiley-VCH:; Wiley-VCH:
Weinheim, 2011; (e) Menezes, P. H.; Zeni, G. Vinyl Selenides Patai’s. In
Chemistry of Functional Groups; John Wiley & Sons, 2011; (f) Petragnani, N.;
As shown in Table 5, compound 3a was effective in inhibiting
the lipid peroxidation induced by SNP in the cortex, the cerebellum
and the hippocampus of mice at a concentration equal to or higher
than 5, 10, or 50 M, respectively. The compound 3j showed a sig-
nificant inhibition of lipid peroxidation in the concentration equal
or higher than 0.1 M in the hippocampus, whereas in the cortex
and the cerebellum starting from a concentration of 1 M (Table
Stefani, H. A. Tellurium in Organic Synthesis, 2nd ed.; Academic Press: London,
2007.
l
2. For Reviews see: (a) Perin, G.; Lenardão, E. J.; Jacob, R. G.; Panatieri, R. B. Chem.
Rev. 2009, 109, 1277; (b) Freudendahl, D. M.; Santoro, S.; Shahzad, S. A.; Santi,
C.; Wirth, T. Angew. Chem., Int. Ed. 2009, 48, 8409; (c) Zeni, G.; Braga, A. L.;
Stefani, H. A. Acc. Chem. Res. 2003, 36, 731; (d) Zeni, G.; Ludtke, D. S.; Panatieri,
R. B.; Braga, A. L. Chem. Rev. 2006, 106, 1032; (e) Freudendahl, D. M.; Shahzad, S.
A.; Wirth, T. Eur. J. Org. Chem. 2009, 1649; (f) Braga, A. L.; Lüdtke, D. S.; Vargas,
F. Curr. Org. Chem. 2006, 10, 1921; (g) Godoi, M.; Paixão, M. W.; Braga, A. L.
Dalton Trans. 2011, 40, 11347.
l
l
3). In fact, organotellurium compounds can protect against the
pro-oxidant effects of peroxynitrite.16
Some studies have described that the toxicity of organosele-
nium and organotellurium compounds could be associated with
the d-aminolevulinate dehydratase (d-ALA-D) inhibition. d-ALA-D
is a sulfhydryl containing enzyme which can be inhibited at differ-
ent pro oxidant situations and this enzyme can be used as a marker
of toxicity .18–20 Thus, based on considerations above, we investi-
gated whether compounds 3a and 3j can inhibit the d-ALA activity.
Our results showed that d-ALA-D activity was not modified under
the tested concentrations for organic compounds 3a and 3j.
In summary, we have demonstrated the efficient synthesis and
antioxidant activity of a range of novel 4-arylchalcogenyl-7-
chloroquinolines. This new class of compounds was synthesized
in high yields by the reaction of 4,7-dichloroquinoline with diaryl
dichalcogenides under simple reaction conditions and tolerates a
range of substituents in the arylchalcogenyl moiety. The obtained
results revealed that compounds 3a and 3j have antioxidant
activity in vitro and the data demonstrated that 3j exhibited a
potent antioxidant effect when compared to 3a. This protocol is
an efficient method to produce new selenium–nitrogen com-
pounds with antioxidant activity.
3. For Book see: Nogueira, C. W.; Rocha, J. B. T. Organoselenium and
organotellurium compounds: Toxicology and pharmacology. In Patai’s
Chemistry of Functional Groups; John Wiley & Sons, 2011.
4. For Reviews see: (a) Parnham, M. J.; Graf, E. Prog. Drug. Res. 1991, 36, 9; (b)
Mugesh, G.; du Mont, W. W.; Sies, H. Chem. Rev. 2001, 101, 2125; (c) Nogueira,
C. W.; Zeni, G.; Rocha, J. B. T. Chem. Rev. 2004, 104, 6255; (d) Alberto, E. E.;
Nascimento, V.; Braga, A. L. J. Braz. Chem. Soc. 2010, 21, 2032; (e) Nogueira, C.
W.; Rocha, J. B. T. J. Braz. Chem. Soc. 2010, 21, 2055; (f) Nogueira, C. W.; Rocha, J.
B. T. Arch. Toxicol. 2011, 85, 1313; (g) Rocha, J. B. T.; Saraiva, R. A.; Garcia, S. C.;
Gravina, F. S.; Nogueira, C. W. Toxicol. Res. 2012, 1, 85.
5. (a) Katritzky, A. R.; Pozharskii, A. F. Handbook of Heterocyclic Chemistry, 2nd ed.;
Pergamon: Oxford, 2000; (b) Eicher, T.; Hauptmann, S. The Chemistry of
Heterocycles, 2nd ed.; Wiley: VCH, 2003.
6. For some examples, see: (a) Larsen, R. D.; Corley, E. G.; King, A. O.; Carrol, J. D.;
Davis, P.; Verhoeven, T. R.; Reider, P. J.; Labelle, M.; Gauthier, J. Y.; Xiang, Y. B.;
Zamboni, R. J. J. Org. Chem. 1996, 61, 3398; (b) Roma, G.; Braccio, M. D.; Grossi,
G.; Mattioli, F.; Ghia, M. Eur. J. Med. Chem. 2000, 35, 1021; (c) Chen, Y. L.; Fang,
K. C.; Sheu, J. Y.; Hsu, S. L.; Tzeng, C. C. J. Med. Chem. 2001, 44, 2374; (d) Gantier,
J. C.; Fournet, A.; Munos, M. H.; Hocquemiller, R. Planta Med. 1996, 62, 285; (e)
Martínez-Grueiro, M.; Giménez-Pardo, C.; Gómez-Barrio, A.; Franck, X.;
Fournet, A.; Hocquemiller, R.; Figadère, B.; Casado-Escribano, N. Farmaco
2005, 60, 219; (f) Fakhfakh, M. A.; Fournet, A.; Prina, E.; Mouscadet, J.-F.;
Franck, X.; Hocquemiller, R.; Figadère, B. Bioorg. Med. Chem. Lett. 2003, 11,
5013; (g) Fournet, A.; Mahieux, R.; Fakhfakh, M. A.; Franck, X.; Hocquemiller,
R.; Figadere, B. Bioorg. Med. Chem. Lett. 2003, 13, 891; (h) Franck, X.; Fournet, A.;
Prina, E.; Mahieux, R.; Hocquemiller, R.; Figadere, B. Bioorg. Med. Chem. Lett.
2004, 14, 3635; (i) Hoemann, M. Z.; Kumaravel, G.; Xie, R. L.; Rossi, R. F.; Meyer,
S.; Sidhu, A.; Cuny, G. D.; Hauske, J. R. Bioorg. Med. Chem. Lett. 2000, 10, 2675.
7. (a) Gottlieb, D.; Shaw, P. D. In Antibiotics II, Biosynthesis; Springer: New York,
1967; Vol. 2,; (b) Font, M; Monge, A.; Ruiz, I.; Heras, B. Drug Des Discovery 1997,
14, 259; (c) Nakamura, T.; Oka, M.; Aizawa, K.; Soda, H.; Fukuda, M.; Terashi, K.;
Ikeda, K.; Mizuta, Y.; Noguchi, Y.; Kimura, Y.; Tsuruo, T.; Kohno, S. Biochem.
Biophys. Res. Commun. 1999, 255, 618; (d) Kaminsky, D.; Meltzer, R. I. J. Med.
Chem. 1968, 11, 160; (e) Musiol, R.; Jampilek, J.; Buchta, V.; Silva, L.; Niedbala,
H.; Podeszwa, B.; Palka, A.; Majerz-Maniecka, K.; Oleksyn, B.; Polanski, J. Bioorg.
Med. Chem. Lett. 2006, 14, 3592; (f) Warshakoon, N. C.; Sheville, J.; Bhatt, R. T.;
Ji, W.; Mendez-Andino, J. L.; Meyers, K. M.; Kim, N.; Wos, J. A.; Mitchell, C.;
Paris, J. L.; Pinney, B. B.; Reizes, O.; Hu, X. E. Bioorg. Med. Chem. Lett. 2006, 16,
5207; (g) Sloboda, A. E.; Powell, D.; Poletto, J. F.; Pickett, W. C.; Gibbons, J. J., Jr.;
Bell, D. H.; Oronsky, A. L.; Kerwar, S. S. J. Rheumatol. 1991, 18, 855.
Acknowledgments
We are grateful to CAPES, CNPq, FINEP, and FAPERGS (PRONEX
10/0027-4 and PRONEM 11/2024-9) for the financial support. L.S.,
E.J.L., and D.A. are recipients of CNPq fellowship.
References and notes
1. For Books see: (a) Wirth, T. Organoselenium Chemistry In Topics in Current
Chemistry; Springer-Verlag: Heidelberg, 2000; (b) Devillanova, F. A. Handbook
of Chalcogen Chemistry: New Perspectives S, Se and Te; Royal Society of
Chemistry: Cambridge, UK, 2006; (c) Alberto, E. E.; Braga, A. L. Selenium and
Tellurium Chemistry - From Small Molecules to Biomolecules and Materials In
Derek, W. J., Risto, L., Eds.; Springer-Verlag: Berlin, Heidelberg, 2011; (d) Wirth,
8. For examples of biological active 7-chloroquinolines see: (a) Macedo, B.;
Kaschula, C. H.; Hunter, R.; Chaves, J. A. P.; van der Merwe, J. D.; Silva, J. L.; Egan,
T. J.; Cordeiro, Y. Eur. J. Med. Chem. 2010, 45, 5468; (b) Candéa, A. L. P.; Ferreira,